TherapeuticsMD Inc (TXMD) earnings · next report Nov 11, 2026
Next report
Wed, Nov 11, 2026
Time not announced · In 7 days
Quarter ended Sep 2026
- EPS consensus
- —
- Revenue consensus
- —
EPS estimate trend
No estimate history stored for this quarter yet.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow TXMD into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 11)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- — No measured TXMD earnings moves stored yet.
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
$0.01
vs — est. —
GAAP diluted EPS, SEC 10-Q
Revenue
$869.00K
No revenue consensus stored
As filed with the SEC
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 1 of 3
- Aug 11, 2026EPS $0.01GAAP vs — —Rev $869.00K vs —
- May 18, 2026In lineEPS $0.00GAAP vs $0.00 —Rev $724.00K vs —
- Nov 12, 2025In lineEPS $0.00GAAP vs $0.00 —Rev $784.00K vs —
- Aug 12, 2025BeatEPS $0.05GAAP vs $0.00 —Rev $952.00K vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Jun 2026 | — | $0.01GAAP | — | — | $869.00KSEC | — |
| May 18, 2026 | Mar 2026 | $0.00 | $0.00GAAP | — | — | $724.00KSEC | — |
| Nov 12, 2025 | Sep 2025 | $0.00 | $0.00GAAP | — | — | $784.00KSEC | — |
| Aug 12, 2025 | Jun 2025 | $0.00 | $0.05GAAP | — | — | $952.00KSEC | — |
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All TXMD filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
TXMD among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- QTTB earnings5.00 · Strong Buy · stock
- AVAH earnings4.99 · Strong Buy · stock
- CDNA earnings4.98 · Strong Buy · stock
- HALO earnings4.97 · Strong Buy · stock
- OSCR earnings4.97 · Strong Buy · stock
- REGN earnings4.95 · Strong Buy · stock
- CON earnings4.94 · Strong Buy · stock
- PACS earnings4.94 · Strong Buy · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | $869.00K | $0.01 | −8.7% |
| Q1 FY26 | $724.00K | $0.01 | +84.2% |
| Q3 FY25 | $784.00K | $0.01 | +43.3% |
| Q2 FY25 | $952.00K | $0.05 | +306.8% |
TherapeuticsMD Inc (TXMD) is a drug manufacturers - specialty & generic company listed on US.
Latest reported TXMD revenue for 2025-12-31 was $3.0M. Net income was -$569.0K. Revenue was up 71.6% from 2024-12-31 to 2025-12-31. TXMD currently screens at market cap $13.7M.
When the next TXMD 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was up 71.6% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full TXMD research stays on the stock page; the tape stays on the quote page.
TXMD earnings FAQ
When is TXMD's next earnings date?
TherapeuticsMD Inc (TXMD) is expected to report on Wed, Nov 11, 2026. This is the provider’s estimated date; the company has not confirmed it.
How often does TXMD beat EPS estimates?
TherapeuticsMD Inc (TXMD) beat the EPS consensus in 1 of its last 6 reported quarters.
What are TXMD's latest revenue and net income?
Latest cached TherapeuticsMD Inc (TXMD) revenue for Dec 31, 2025 was $3.0M. Net income was -$569.0K. Statements: https://lician.com/financials/txmd
What is TXMD's latest diluted EPS?
Latest cached TherapeuticsMD Inc (TXMD) diluted EPS for Dec 31, 2025 was -$0.05.
What period does the latest TXMD earnings print cover?
The latest cached TherapeuticsMD Inc (TXMD) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did TXMD revenue change from the prior cached period?
Cached TherapeuticsMD Inc (TXMD) revenue was up 71.6% from $1.8M (Dec 31, 2024) to $3.0M (Dec 31, 2025). Statements: https://lician.com/financials/txmd
Where are TXMD earnings listed?
Cached earnings facts for TherapeuticsMD Inc (TXMD) are listed at https://lician.com/earnings/txmd. Statements: https://lician.com/financials/txmd
Not investment advice.